The Board is responsible for setting the Company’s strategy and ensuring that appropriate controls, decision-making processes and resources are in place to deliver long-term shareholder value. Following a strategic review in late 2025, CelLBxHealth has repositioned its business towards a commercially focused, partner-led model centred on product sales, laboratory services and the development of laboratory-developed tests. The strategy prioritizes revenue growth, cost discipline and the expansion of strategic partnerships, particularly in the United States and other key markets.
Corporate governance
AIM rule 50